leishmanias
complex
diseas
caus
protozoan
parasit
genu
leishmania
million
case
report
worldwid
million
peopl
risk
develop
estim
sever
form
viscer
leishmaniasi
vl
caus
death
per
measur
control
transmiss
parasit
limit
success
date
despit
advanc
treatment
vl
last
decad
drug
toxic
heat
stabil
difficult
rout
administr
variat
drug
efficaci
endem
area
remain
issu
fulli
solv
prevent
therapeut
leishmaniasi
vaccin
prospect
repres
costeffect
success
measur
control
leishmanias
immun
intracellular
parasit
leishmania
associ
tcellmedi
immun
dna
vaccin
particularli
abl
deliv
antigen
major
histocompat
complex
class
process
pathway
therebi
induc
cytotox
tcell
immun
necessari
clearanc
leishmania
addit
cell
b
cell
activ
dna
vaccin
henc
vaccin
technolog
promis
approach
develop
leishmaniasi
appropri
preclin
safeti
profil
vaccin
candid
establish
prior
initi
clinic
phase
studi
us
food
drug
administr
fda
world
health
organ
recommend
evalu
distribut
persist
dna
vaccin
well
local
reactogen
system
result
correspond
studi
suggest
dna
vaccin
confirm
sever
clinic
howev
immunogen
dna
vaccin
often
modest
human
necessit
better
deliveri
method
improv
vaccin
antigen
addit
safeti
concern
prompt
avoid
antibiot
resist
gene
select
marker
plasmid
stateoftheart
plasmid
consequ
efficaci
safer
smaller
classic
minimalist
immunogen
defin
gene
express
midg
vector
repres
one
rigor
concept
midg
vector
small
linear
doublestrand
dna
dsdna
molecul
sole
contain
sequenc
requir
function
vivo
bacteri
plasmid
backbon
sequenc
shown
neg
impact
transgen
express
vector
midg
vector
short
peptid
pkkkrkvedpyc
coval
attach
enhanc
immun
respons
encod
recent
preclin
data
biodistribut
toxic
midg
vector
indic
excel
safeti
profil
singl
administr
leishdnavax
mixtur
five
vector
encod
differ
leishmania
antigen
cpa
cpb
elong
factor
antigen
select
sequenc
design
follow
novel
ration
approach
seri
anim
experi
demonstr
leishdnavax
immunogen
effect
challeng
leishmania
donovani
caus
agent
vaccin
aim
administ
human
prevent
therapeut
set
present
comprehens
preclin
safeti
toler
data
leishdnavax
repeateddos
toxic
studi
naiv
mice
biodistribut
persist
studi
rat
perform
moreov
effect
leishdnavax
administr
parasit
burden
standard
toler
paramet
mous
model
vl
evalu
studi
potenti
cumul
effect
repeat
dose
leishdnavax
address
allow
better
riskassess
prior
multidos
clinic
trial
biodistribut
vaccin
assess
rat
intraderm
id
inject
dose
total
dna
extract
tissu
sampl
taken
h
post
inject
vector
dna
quantifi
use
quantit
pcr
qpcr
assay
vector
dna
found
vari
number
anim
per
group
tissu
except
bone
marrow
figur
vector
copi
number
per
total
dna
rang
geometr
mean
ovari
anim
posit
geometr
mean
skin
inject
site
anim
posit
next
test
whether
repeat
administr
alter
distribut
pattern
caus
accumul
vector
dna
tissu
one
hundr
twenti
microgram
leishdnavax
administ
rat
id
site
four
time
weekli
interv
vector
dna
quantifi
total
dna
extract
tissu
sampl
collect
h
last
inject
distribut
pattern
amount
vector
dna
compar
h
singl
repeat
inject
figur
b
copi
number
per
total
dna
rang
geometr
mean
lung
tissu
anim
posit
geometr
mean
skin
inject
site
anim
posit
persist
vector
examin
day
day
post
treatment
fourteen
day
four
inject
leishdnavax
clear
major
organ
figur
high
vector
copi
number
per
total
dna
found
skin
inject
site
anim
posit
geometr
mean
copi
inguin
lymph
node
anim
posit
geometr
mean
copi
sixti
day
four
inject
vector
clear
tissu
persist
inguin
lymph
node
anim
posit
geometr
mean
copi
skin
inject
site
anim
posit
geometr
mean
copi
figur
assess
toxic
leishdnavax
naiv
mice
steril
phosphatebuff
salin
pb
placebo
ascend
dose
vaccin
inject
either
five
time
weekli
interv
tabl
leishdnavax
well
toler
dose
test
anim
die
inlif
phase
chang
behavior
extern
appear
anim
note
compar
placebotr
leishdnavaxtr
anim
differ
observ
bodi
weight
food
drink
water
consumpt
ophthalmolog
auditori
examin
urinalysi
organ
weight
neurolog
screen
local
intoler
reaction
note
singl
repeat
vaccin
dose
minor
deviat
singl
animalsgroup
blood
paramet
larg
unstain
cell
albuminglobulin
ratio
classifi
vaccinerel
macroscop
post
mortem
examin
organ
reveal
enlarg
spleen
singl
male
anim
day
singl
administr
leishdnavax
possibl
indic
activ
lymphat
system
anim
histolog
find
within
normal
rang
variat
leishdnavaxrel
morpholog
lesion
found
sign
autoimmun
reaction
observ
elev
level
serum
antibodi
dsdna
detect
biolog
activ
vaccin
lot
proven
induct
antigenspecif
serum
immunoglobulin
g
igg
mice
satellit
group
tabl
dosedepend
increas
leishdnavaxspecif
igg
level
observ
figur
line
data
efficaci
studi
previous
rat
receiv
vaccin
biodistribut
studi
exhibit
vaccinerel
local
system
sign
toxic
also
necropsi
reveal
vaccinerel
toxic
toler
leishdnavax
effect
viscer
parasit
burden
evalu
balbc
mice
group
mice
infect
l
donovani
inject
one
two
three
dose
leishdnavax
pb
weekli
interv
parasit
burden
evalu
seven
day
day
last
inject
signific
differ
hepat
splenic
parasit
burden
found
group
receiv
equal
number
inject
pb
leishdnavax
treatment
group
infect
l
donovani
follow
known
distinct
organspecif
growth
pattern
liver
spleen
infect
mice
figur
show
parasit
burden
determin
balbc
one
experi
signific
differ
weight
pb
leishdnavaxtr
group
mice
observ
serum
sampl
mice
receiv
three
inject
pb
leishdnavax
subject
analys
standard
biochem
paramet
alanin
transaminas
aspart
aminotransferas
urea
creatinin
signific
differ
pb
leishdnavaxtr
group
found
paramet
balbc
mice
signific
differ
found
level
creatinin
mice
two
separ
experi
howev
neither
time
point
direct
differ
consist
experi
tabl
histolog
analysi
liver
spleen
repeat
experi
kidney
heart
lung
singl
experi
mice
reveal
similar
lesion
anim
pb
leishdnavax
treat
term
locat
sever
lesion
consist
infect
includ
sever
granulomat
hepat
spleniti
intralesion
parasit
granulomatousinterstiti
pneumonia
interstiti
nephriti
glomerulonephr
biodistribut
persist
dna
vaccin
studi
estim
durat
antigen
express
risk
vector
integr
host
genom
examin
biodistribut
leishdnavax
singl
contrast
previous
publish
also
seri
four
inject
weekli
interv
condens
applic
scheme
relev
clinic
approach
limit
number
inject
longer
period
time
accept
prophylact
vaccin
ii
vaccin
regim
requir
inject
shorter
interv
exampl
therapeut
vaccin
line
recommend
us
organ
tissu
sampl
taken
sever
time
point
follow
inject
vector
dna
quantifi
use
quantit
pcr
twentyfour
hour
singl
repeat
inject
vector
dna
detect
almost
organ
tissu
examin
suggest
distribut
system
like
via
lymphat
system
blood
stream
similar
distribut
pattern
describ
vector
encod
hepat
b
surfac
indic
distribut
vector
independ
encod
protein
previous
report
plasmid
dna
system
distribut
earli
time
point
also
shown
nake
plasmid
dna
upon
im
id
accord
highest
vector
amount
detect
sampl
taken
site
inject
consist
lymph
node
drain
site
inject
contain
second
highest
copi
number
probabl
due
skin
immun
cell
take
dna
site
inject
migrat
lymph
node
day
fourth
inject
vector
clear
nearli
organ
except
skin
inguin
lymph
node
wherea
amount
vector
dna
skin
sampl
lower
compar
h
last
inject
vector
copi
number
inguin
lymph
node
sampl
reduc
find
line
report
idadminist
plasmid
dna
suggest
plasmid
vector
report
follow
similar
pattern
distribut
persist
vector
dna
clear
skin
inguin
lymph
node
within
day
four
inject
although
also
observ
follow
singl
id
administr
vector
encod
hepat
b
surfac
contrast
find
tumor
necrosi
factor
alphaencod
midg
vector
clear
inject
site
tissu
mice
within
h
intratumor
jet
short
time
overal
clearanc
probabl
relat
wider
dispers
dna
upon
multipl
jet
inject
lower
dna
concentr
five
jet
inject
dna
mg
versu
one
needl
inject
dna
mg
well
rapid
entri
blood
circuit
due
high
vascular
low
retent
rate
macromolecul
tumor
tissu
compar
normal
skin
tissu
though
sidebysid
comparison
would
conclus
propos
paramet
strongli
affect
time
overal
clearanc
dna
dose
fact
rat
studi
receiv
leishdnavax
dna
per
gram
bodi
weight
thu
lower
rel
dna
dose
administ
mice
referenc
studi
tumor
necrosi
factor
alpha
midg
dna
per
gram
bodi
weight
persist
least
day
observ
studi
suggest
vector
dna
enter
longliv
cell
resid
skin
whether
vector
dna
still
function
conclud
result
quantit
pcr
method
target
short
consensu
sequenc
notabl
vector
dna
accumul
tissu
repeat
inject
day
one
four
inject
leishdnavax
compar
amount
vector
dna
found
indic
repeat
inject
enhanc
persist
therefor
futur
evalu
biodistribut
persist
vector
similar
set
base
singl
inject
longterm
persist
vector
dna
tissu
relat
integr
host
genom
dna
thu
theoret
bear
tumorigen
potenti
howev
publish
data
show
integr
rate
plasmid
dna
vector
exceed
rate
spontan
mutat
event
within
host
notabl
linear
dna
vector
structur
similar
midg
vector
low
level
integr
furthermor
contrast
close
circular
plasmid
dna
molecul
integr
coval
close
linear
dna
construct
rather
lead
disrupt
chromosom
follow
apoptosi
affect
cell
henc
minim
risk
replic
unwant
genet
basi
publish
result
risk
relat
potenti
integr
vector
host
genom
dna
consid
low
though
assess
work
repeateddos
toxic
studi
naiv
mice
test
three
ascend
dose
leishdnavax
highest
dose
correspond
human
dose
mg
dna
mg
bodi
weight
base
dose
publish
clinic
trial
rang
plasmid
dna
studi
design
includ
high
safeti
margin
extend
safeti
margin
vaccin
administ
condens
schedul
five
vaccin
one
estim
maximum
number
clinic
applic
weekli
interv
importantli
observ
advers
effect
level
highest
dose
without
signific
toxic
reach
dose
test
local
intoler
reaction
relat
vaccin
observ
result
establish
naiv
mice
corrobor
safeti
data
obtain
biodistribut
studi
rat
receiv
leishdnavax
correspond
human
dose
mg
base
mg
bodi
weight
vaccinerel
toxic
effect
observ
either
result
confirm
find
investig
report
excel
preclin
safeti
profil
dna
leishmaniainfect
diseas
individu
toler
vaccin
may
differ
healthi
naiv
vaccine
moreov
owe
abil
leishmania
amastigot
exploit
host
igg
virul
theoret
risk
vaccinerel
immuneenhanc
infect
pathogenesi
discuss
infecti
henc
demonstr
absenc
diseas
exacerb
includ
develop
program
leishdnavax
evalu
toler
leishdnavax
two
differ
mous
strain
chosen
inher
differ
cytokin
respons
infect
l
experi
demonstr
leishdnavax
effect
kinet
parasit
burden
vaccinerel
enhanc
infect
time
point
investig
kinet
infect
correspond
welldocu
pattern
mice
rapid
increas
hepat
parasit
burden
follow
declin
parasit
number
clearanc
slower
increas
parasit
number
spleen
establish
chronic
result
standard
paramet
similar
treat
nontreat
mice
demonstr
good
toler
vaccin
candid
infect
anim
summari
shown
leishdnavax
novel
dna
vaccin
candid
leishmaniasi
safe
well
toler
naiv
leishmaniainfect
mice
repeat
id
inject
vaccin
rapidli
clear
organ
tissu
rat
persist
skin
inject
site
drain
lymph
node
conclud
leishdnavax
favor
safeti
profil
support
initi
human
clinic
trial
leishdnavax
equimass
mixtur
five
vector
dissolv
steril
pb
vector
encod
one
leishmania
antigen
cpa
cpb
tsa
respect
dna
sequenc
express
cassett
vector
describ
vector
synthes
simpl
standard
leishdnavax
prepar
concentr
mg
total
dna
pb
control
process
subsequ
qualiti
control
mologen
ag
berlin
germani
vaccin
fill
readytous
solut
inject
vial
sent
frozen
test
facil
aurigon
life
scienc
tutz
germani
perform
inlif
phase
accord
good
laboratori
practic
glp
regul
accord
german
anim
welfar
regul
experiment
design
review
approv
local
govern
govern
upper
bavaria
amt
verbraucherschutz
und
registr
studi
forti
wistar
rat
per
sex
janvier
lab
saintberthevin
franc
week
age
alloc
singl
fourdos
studi
group
anim
five
per
sex
anim
receiv
needl
inject
leishdnavax
per
inject
vector
molecul
inject
volum
id
dorsal
base
tail
either
four
time
weekli
interv
anim
inject
singl
dose
kill
h
administr
fourdos
group
either
kill
h
day
day
fourth
inject
clinic
sign
record
min
h
treatment
thereaft
daili
twentyfour
hour
inject
modifi
irwin
perform
singledos
group
nontreat
control
group
assess
acut
neurolog
toxic
vaccin
throughout
studi
mortal
evalu
daili
bodi
weight
weekli
kill
anim
anesthet
deepli
isofluran
inhal
blood
collect
plexu
ophthalmicu
gross
patholog
perform
sampl
follow
tissu
taken
blood
thigh
bone
marrow
brain
heart
kidney
liver
lobu
quadratu
lymph
node
lnn
axillar
inguinal
mesenterial
lung
thigh
muscl
ovari
skin
inject
site
spleen
test
avoid
crosscontamin
vector
dna
singleus
scalpel
appli
sampl
equip
thoroughli
decontamin
dissect
sampl
immedi
frozen
liquid
nitrogen
store
process
quantit
analys
dna
vector
amount
perform
imgm
laboratori
martinsri
germani
total
dna
extract
mg
tissu
blood
respect
use
dneasi
blood
tissu
kit
qiagen
hilden
germani
store
taqmanbas
quantit
realtimepcr
assay
establish
character
use
standard
curv
leishdnavax
rang
vector
copi
per
reaction
vector
copi
per
reaction
ng
genom
dna
liver
naiv
anim
background
measur
carri
ng
extract
total
dna
well
plate
reaction
volum
instrument
life
technolog
carlsbad
ca
usa
primer
eurofin
genom
ebersberg
germani
hydrolysi
mgb
probe
life
technolog
design
detect
consensu
sequenc
present
vector
forward
primer
anneal
cmv
promot
region
hydrolysi
mgb
probe
revers
primer
anneal
intron
limit
detect
lower
limit
quantif
assay
determin
copi
vector
per
reaction
copi
per
total
dna
sampl
extract
dna
measur
triplic
vector
copi
number
calcul
accord
leishdnavax
standard
curv
run
parallel
plate
express
copi
number
per
total
dna
accept
criteria
measur
includ
standard
curv
coeffici
correl
detect
copi
number
notemplatecontrol
limit
detect
addit
sd
quantif
cycl
valu
least
two
replic
measur
otherwis
measur
repeat
studi
perform
accord
glp
regul
principl
german
anim
welfar
regul
lpt
laboratori
pharmacolog
toxicolog
hamburg
germani
prior
approv
lpt
institut
anim
care
use
commissari
studi
compet
author
gesundheit
und
verbraucherschutz
amt
verbraucherschutz
lebensmittelsicherheit
und
hamburg
germani
v
one
hundr
forti
balbc
mice
male
femal
random
alloc
studi
group
anim
hous
individu
first
treatment
mice
day
male
day
femal
age
bodi
weight
g
male
g
femal
ten
anim
five
per
sex
receiv
one
id
needl
inject
volum
dorsal
tail
base
dose
leishdnavax
placebo
pb
kill
h
post
inject
evalu
acut
toxic
reaction
thirti
anim
receiv
placebo
dose
anim
receiv
dose
inject
volum
inject
needl
id
dorsal
tail
base
five
time
weekli
interv
anim
kill
recoveri
period
h
day
day
placebo
dose
group
follow
fifth
inject
tabl
anim
observ
clinic
sign
includ
inject
site
reactogen
min
h
dose
daili
inject
mortal
evalu
twice
daili
throughout
studi
bodi
weight
anim
record
day
group
alloc
day
first
dose
three
time
week
thereaft
food
consumpt
determin
weekli
water
consumpt
record
daili
neurolog
assess
grip
conduct
anim
h
first
dose
ophthalmolog
auditori
examin
perform
predos
end
treatment
period
end
recoveri
period
urinalysi
mice
place
funnel
cage
group
five
per
sex
receiv
ml
tap
water
per
kg
bodi
weight
gavag
subsequ
urin
collect
h
follow
paramet
measur
volum
weight
ph
specif
graviti
osmol
protein
glucos
bilirubin
urobilinogen
keton
hemoglobin
nitrit
epitheli
cell
leukocyt
erythrocyt
organ
constitu
crystalluria
kill
blood
taken
clinic
biochemistri
albumin
globulin
bilirubin
cholesterol
triglycerid
creatinin
glucos
protein
urea
calcium
alanin
aminotransferas
alkalin
phosphatas
aspart
aminotransferas
creatin
kinas
glutamatedehydrogenas
lactat
dehydrogenas
hematolog
hemoglobin
content
erythrocyt
leukocyt
differenti
blood
count
reticulocyt
platelet
mean
platelet
volum
red
cell
distribut
width
hematocrit
mean
corpuscular
volum
mean
corpuscular
hemoglobin
mean
corpuscular
hemoglobin
concentr
gross
patholog
examin
conduct
organ
weight
taken
sampl
follow
organ
tissu
process
histolog
examin
adren
gland
aorta
abdominali
bone
os
femori
joint
bone
marrow
brain
cecum
coagul
gland
semin
vesicl
epididymi
eye
optic
nerv
harderian
gland
exorbit
lacrim
gland
gall
bladder
heart
skin
subcutan
tissu
inject
site
larg
intestin
small
intestin
kidney
uret
liver
lung
lymph
node
mandibular
mesenter
mammari
gland
muscl
sciatic
nerv
esophagu
ovari
pancrea
pituitari
gland
prostat
salivari
gland
spinal
cord
spleen
sternum
stomach
testicl
thymu
thyroid
tongu
trachea
urinari
bladder
uteru
vagina
histolog
examin
perform
sampl
anim
highest
expect
burden
receiv
five
inject
leishdnavax
h
recoveri
respect
placebo
group
control
moreov
immunolog
relev
organ
thymu
spleen
lymph
node
well
skin
inject
site
anim
group
examin
histolog
gener
tissu
sampl
fix
buffer
formalin
eye
davidson
solut
embed
paraffin
section
prepar
routin
stain
haematoxylineosin
sampl
mice
receiv
five
time
dose
respect
schedul
histolog
examin
case
vaccinerel
find
group
receiv
five
time
gross
patholog
reveal
vaccinerel
chang
respect
find
sampl
histolog
examin
balbc
mice
male
femal
random
alloc
satellit
studi
group
toxic
studi
resembl
repeateddos
treatment
schedul
tabl
first
treatment
anim
day
male
day
femal
age
bodi
weight
g
male
femal
studi
termin
blood
sampl
taken
serum
obtain
enzymelink
immunosorb
assay
test
antibodi
vaccin
antigen
radioimmunoassay
test
antibodi
dsdna
analys
perform
nonglp
regul
condit
leishdnavaxspecif
antibodi
detect
perform
enzymelink
immunosorb
assay
previous
minor
modif
plate
nunc
maxisorp
thermo
scientif
roskild
denmark
coat
per
well
antigenmix
cpa
cpb
tsa
pb
fisher
scientif
paisley
uk
recombin
protein
obtain
proteogenix
oberhausbergen
franc
cpa
cpb
tsa
kindli
provid
professor
c
jaff
antigen
mix
assembl
lpt
plate
incub
overnight
wash
three
time
wash
buffer
vv
tween
pb
subsequ
block
assay
diluent
wv
bovin
serum
albumin
sigma
aldrich
st
loui
usa
pb
h
room
temperatur
plate
wash
three
time
wash
buffer
per
well
dilut
serum
sampl
ad
plate
incub
h
room
temperatur
subsequ
wash
five
time
wash
buffer
hundr
micolitr
per
well
antimous
igghrp
conc
mg
sigma
aldrich
ad
dilut
plate
incub
h
room
temperatur
wash
five
time
develop
solut
contain
sigma
aldrich
ad
reaction
stop
ad
acid
solut
color
develop
absorb
measur
nm
assess
induct
immun
respons
dsdna
radioimmunoassay
perform
ibl
intern
gmbh
hamburg
germani
use
kit
detect
antidsdna
antibodi
ibl
intern
brief
serum
sampl
mix
dsdna
tracer
incub
min
subsequ
ml
cold
ammonium
sulfat
solut
ad
sampl
follow
vortex
tube
centrifug
min
g
supernat
remov
radioact
count
use
gamma
counter
dsdna
bind
capac
calcul
accord
standard
curv
balbcanncrl
ko
mice
charl
river
margat
uk
maintain
specif
pathogenfre
condit
individu
ventil
cage
expos
h
h
dark
cycl
standard
rodent
diet
rm
expand
deioniz
water
suppli
ad
libitum
l
donovani
strain
maintain
ko
mice
amastigot
harvest
spleen
infect
anim
day
infect
femal
balbc
mice
week
age
start
experi
infect
inject
freshli
harvest
l
donovani
amastigot
intraven
tail
vein
follow
infect
anim
sort
group
three
five
mice
per
cage
two
cage
assign
treatment
group
group
mice
receiv
either
one
two
three
inject
leishdnavax
contain
dnaantigen
correspond
total
dna
pb
administ
volum
id
base
tail
use
singleus
needl
bd
microfin
plu
insulin
syring
first
dose
administ
day
infect
repeat
dose
interv
group
mice
kill
day
receiv
last
dose
leishdnavax
pb
experi
mice
addit
group
kill
day
last
total
three
dose
leishdnavax
pb
mous
weight
record
prior
first
dose
treatment
administ
weekli
interv
thereaft
inject
site
monitor
follow
administr
treatment
anim
observ
daili
train
staff
whole
durat
experi
mice
human
kill
exsanguin
termin
anesthesia
blood
collect
cardiac
punctur
liver
spleen
remov
weight
record
tissu
impress
smear
prepar
fix
methanol
stain
giemsa
parasit
burden
determin
microscop
leishmandonovan
unit
calcul
formula
number
parasit
per
host
cell
nucleu
organ
weight
mg
describ
serum
harvest
blood
store
overnight
centrifug
g
min
store
biochem
analysi
standard
serum
paramet
carri
laboklin
gmbh
cokg
bad
kissingen
germani
histolog
organ
fix
neutral
buffer
formalin
embed
paraffin
routin
stain
hematoxylin
eosin
histolog
data
evalu
blind
fashion
data
repeateddos
toxic
studi
naiv
mice
analyz
use
student
ttest
numer
function
test
dunnet
multipl
ttest
bodi
weight
food
consumpt
hematolog
clinic
biochemistri
organ
weight
fisher
exact
test
histolog
respect
toxic
data
biodistribut
studi
evalu
follow
paramet
irwin
test
analyz
utest
normal
bodi
weight
data
test
case
normal
analysi
varianc
perform
post
hoc
dunnett
test
multipl
comparison
otherwis
nonparametr
test
post
hoc
dunnett
test
employ
igg
level
statist
analyz
use
graphpad
prism
graphpad
softwar
inc
la
jolla
usa
normal
data
test
shapirowilk
test
prior
appli
either
twotail
student
ttest
test
analyz
differ
mean
two
group
evalu
toler
vaccin
infect
mice
comparison
three
group
made
oneway
analysi
varianc
follow
bonferroni
multipl
comparison
test
comparison
pb
vaccin
treat
group
comparison
two
group
made
unpair
ttest
assum
gaussian
distribut
graphpad
prism
pvalu
consid
statist
signific
